A210 THE BURDEN OF IBD HOSPITALIZATION IN CANADA: AN ASSESSMENT OF THE CURRENT AND FUTURE BURDEN IN A NATION-WIDE ANALYSIS

Abstract Background Hospitalizations pose a significant burden on both the individual and healthcare system. Those with inflammatory bowel disease (IBD) are at increased risk of hospitalization as compared to general population due flaring activity complications related IBD. The advent biologics over past twenty years may have influenced rates for Purpose To assess current forecast overall those IBD stratified by types hospitalizations (all cause hospitalizations, IBD-related, IBD-specific). Method Population-based administrative data (2002-2014) were obtained from: AB, BC, MB, SK. Data age sex standardized matching year aggregated into representative sample Canadian population. Hospitalization assessed follows: 1. All hospitalizations: all admissions regardless indication; 2. IBD-specific: an admission directly resulting from (e.g., IBD-flare); 3. IBD-related: IBD, or symptom comorbidity associated (e.g. rheumatoid arthritis). Using prevalence estimates provinces, (per 100 persons IBD) calculated, 95% confidence intervals (CI). Autoregressive Integrated Moving Average models created estimate number corresponding 2030 prediction (PI). Poisson (or negative binomial) regression estimated Annual Percentage Change (AAPC), CIs, forecasted data. Result(s) In 2002 there 35.3 per (95%CI: 34.7, 35.9) patients this decreased 24.9 (24.5, 25.2) in 2014. Similar trends seen IBD-specific [16.8 16.4, 17.2) 8.7 8.5, 9.0) 2014] IBD-related (22.6 22.1, 23.1) 13.4 13.2, 13.7) 2014). When out significantly decreasing—the AAPC was -2.12% -2.31, -1.93), -3.77% -4.63, -3.08) IBD-specific, -3.09% -3.65, -2.62) IBD-related. By 2030, be 17.0 (95%PI: 16.2, 17.9), 4.6 3.7, 5.4), 7.9 6.9, 8.9) cause, respectively. Image Conclusion(s) Canada, use anti-TNF therapy conjunction evolution clinical monitoring, management guidelines, likely has contributed dropping rates. Forecast continued drop 2030. Importantly, resource planning should account shift hospital-based clinic-centric care. Please acknowledge funding agencies checking applicable boxes below CIHR Disclosure Interest S. Coward: None Declared, E. Benchimol Consultant of: Hoffman La-Roche Limited Peabody & Arnold LLP matters unrelated medications used treat McKesson Canada Dairy Farmers Ontario disease., C. Bernstein Grant / Research support Unrestricted educational grants Abbvie Janssen Pfizer Bristol Myers Squibb Takeda Canada. Has received research Amgen Sandoz contract Janssen, Pfizer, JAMP Pharmaceuticals, Takeda., Speakers bureau J. A. Avina-Zubieta: Bitton: L. Hracs: Jones Abbvie, Takeda, Kuenzig: Lu: Murthy: Z. Nugent: Otley AbbVie Advisory boards Nestle, R. Panaccione Abbott, AbbVie, Alimentiv (formerly Robarts), Amgen, Arena AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cosmos Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, Bio, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pendopharm, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Theravance Biopharma, Trellus, Viatris, UCB. Boards for: J.-N. Pena-Sanchez: H. Singh Roche Guardant Inc.,, Targownik Investigator initiated [Advisory board] Merck Windsor: G. Kaplan GlaxoSmith Gilead,